ALLO
Price:
$2
Market Cap:
$487.74M
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymp...[Read more]
Industry
Biotechnology
IPO Date
2018-10-11
Stock Exchange
NASDAQ
Ticker
ALLO
According to Allogene Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.60. This represents a change of 25.86% compared to the average of -2.07 of the last 4 quarters.
The mean historical PE Ratio of Allogene Therapeutics, Inc. over the last ten years is -61133.02. The current -2.60 PE Ratio has changed -99.57% with respect to the historical average. Over the past ten years (40 quarters), ALLO's PE Ratio was at its highest in in the June 2025 quarter at -1.23. The PE Ratio was at its lowest in in the December 2017 quarter at -137535.24.
Average
-61133.02
Median
-11.13
Minimum
-550140.95
Maximum
-1.54
Discovering the peaks and valleys of Allogene Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 24.41%
Maximum Annual PE Ratio = -1.54
Minimum Annual Increase = -100.00%
Minimum Annual PE Ratio = -550140.95
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -1.57 | -2.41% |
| 2024 | -1.61 | 5.06% |
| 2023 | -1.54 | -41.89% |
| 2022 | -2.64 | -76.26% |
| 2021 | -11.13 | -8.24% |
| 2020 | -12.13 | -14.53% |
| 2019 | -14.20 | 24.41% |
| 2018 | -11.41 | -100.00% |
The current PE Ratio of Allogene Therapeutics, Inc. (ALLO) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.57
5-year avg
-3.70
10-year avg
-61133.02
Allogene Therapeutics, Inc.’s PE Ratio is less than Editas Medicine, Inc. (-2.19), less than Cabaletta Bio, Inc. (-1.44), less than Caribou Biosciences, Inc. (-1.15), less than Atea Pharmaceuticals, Inc. (-2.07), less than Humacyte, Inc. (-1.57), less than Vanda Pharmaceuticals Inc. (-1.43), less than Voyager Therapeutics, Inc. (-1.88), less than Kyverna Therapeutics, Inc. (-2.46), greater than Achieve Life Sciences, Inc. (-4.33), less than Immutep Limited (-0.92),
| Company | PE Ratio | Market cap |
|---|---|---|
| -2.19 | $263.35M | |
| -1.44 | $463.08M | |
| -1.15 | $162.66M | |
| -2.07 | $348.92M | |
| -1.57 | $155.30M | |
| -1.43 | $348.79M | |
| -1.88 | $224.77M | |
| -2.46 | $353.40M | |
| -4.33 | $497.90M | |
| -0.92 | $55.15M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Allogene Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Allogene Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Allogene Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Allogene Therapeutics, Inc. (ALLO)?
What is the highest PE Ratio for Allogene Therapeutics, Inc. (ALLO)?
What is the 3-year average PE Ratio for Allogene Therapeutics, Inc. (ALLO)?
What is the 5-year average PE Ratio for Allogene Therapeutics, Inc. (ALLO)?
How does the current PE Ratio for Allogene Therapeutics, Inc. (ALLO) compare to its historical average?